Related Experiment Video
Updated: Mar 11, 2026

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections
Kyle C Molina1, Vanthida Huang2
1Department of Pharmacy Practice, College of Pharmacy-Glendale, Midwestern University, 19555 N. 59th Ave., Glendale, AZ, 85308, USA.
Abstract:
The role of vancomycin in the treatment of serious Staphylococcus aureus infections, both methicillin-susceptible and methicillin-resistant, is becoming increasingly ineffective due to increasing MIC and failure. The development of reduced vancomycin susceptibility by S. aureus to glycopeptides highlights the need for clinicians to reexamine the roles of non-glycopeptide therapy. As the use of these alternative non-glycopeptides antimicrobials increases, it will become pertinent to monitor the rates of resistance. Large surveillance programs have provided data for resistance against S. aureus for the non-glycopeptides (daptomycin, ceftaroline, tigecycline, linezolid, and tedizolid). The current published literatures suggest that worldwide resistance rates to these non-glycopeptides for serious MRSA infections are still low. Implementation of antimicrobial stewardship programs will be crucial in prevention of resistance of these antimicrobials against S. aureus.
Insights
Vancomycin is failing against serious Staphylococcus aureus infections. Alternative non-glycopeptide antibiotics show low resistance rates, but monitoring is crucial.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Vancomycin's effectiveness against serious Staphylococcus aureus infections, including methicillin-resistant strains (MRSA), is declining due to rising Minimum Inhibitory Concentrations (MICs) and treatment failures.
- Increasing reduced susceptibility of S. aureus to glycopeptides necessitates a reevaluation of alternative, non-glycopeptide therapeutic options.
Approach:
- Review of large-scale surveillance programs and published literature on S. aureus resistance patterns.
- Focus on non-glycopeptide antimicrobials such as daptomycin, ceftaroline, tigecycline, linezolid, and tedizolid.
Key Points:
- Worldwide resistance rates to key non-glycopeptide antibiotics against serious MRSA infections remain low.
- Surveillance data indicates continued efficacy for alternative therapies when vancomycin susceptibility is compromised.
Conclusions:
- Continued monitoring of resistance trends for non-glycopeptide antimicrobials is essential as their use increases.
- Implementation of robust antimicrobial stewardship programs is critical to preserve the effectiveness of these alternative agents against S. aureus.
Related Concept Videos
Development of Antibiotic Resistance
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Antibiotic Selection
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Gene Regulation in Microbial Communities: Quorum Sensing

